TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from FOXO Technologies ( (FOXO) ).
On September 10, 2025, the majority stockholder of FOXO Technologies Inc., controlled by Rennova Health, Inc., approved an amendment to increase the authorized shares of Class A Common Stock from 500 million to 2.5 billion shares. This decision, made by written consent, allows the company’s board to implement the increase at their discretion before March 31, 2026, without further stockholder approval. The company will file the necessary information with the SEC, and the changes will become effective 20 days after mailing the definitive Information Statement to stockholders.
Spark’s Take on FOXO Stock
According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.
FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.
To see Spark’s full report on FOXO stock, click here.
More about FOXO Technologies
Average Trading Volume: 7,759,885
Technical Sentiment Signal: Sell
Current Market Cap: $242.6K
Find detailed analytics on FOXO stock on TipRanks’ Stock Analysis page.